Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 4Completed 4Unknown 3Approved for marketing 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1

Conditions

Leukemia 3Recurrence 2Lymphoma, Non-Hodgkin 1Leukemia, Hairy Cell 1

Interventions

Cytarabine 102Cyclophosphamide 74fludarabine 45Idarubicin 39Decitabine 36Etoposide 35Azacitidine 34Methotrexate 31Daunorubicin 30Vincristine 28Dexamethasone 27venetoclax 25Busulfan 24Imatinib Mesylate 23Radiotherapy 20Mercaptopurine 20Granulocyte Colony-Stimulating Factor 20Dasatinib 19Peripheral Blood Stem Cell Transplantation 18Mitoxantrone 17Doxorubicin 17Immunotherapy, Adoptive 16Rituximab 15Asparaginase 15Tretinoin 14Cladribine 14fludarabine phosphate 13Prednisone 13Prednisolone 13Melphalan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × immunotoxin HA22 × Other hematologic neoplasm × Clear all
NCT00515892 2007-08-14

NHL

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin

NCT00462189 2007-04-18

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Recurrence

NCT00457860 2007-04-17

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡